MetLife Investment Management’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.68M | Buy |
49,081
+1,045
| +2% | +$67.1K | 0.02% | 810 |
|
|
2026
Q1 | $2.71M | Sell |
48,036
-1,117
| -2% | -$72.7K | 0.01% | 903 |
|
|
2025
Q4 | $3.94M | Sell |
49,153
-3,242
| -6% | -$218K | 0.02% | 741 |
|
|
2025
Q3 | $2.55M | Sell |
52,395
-278,692
| -84% | -$17.3M | 0.01% | 970 |
|
|
2025
Q2 | $24.7M | Buy |
331,087
+14,545
| +5% | +$963K | 0.15% | 112 |
|
|
2025
Q1 | $20.1M | Buy |
316,542
+258,776
| +448% | +$17.6M | 0.11% | 155 |
|
|
2024
Q4 | $4.51M | Buy |
57,766
+3,241
| +6% | +$260K | 0.02% | 616 |
|
|
2024
Q3 | $4.38M | Sell |
54,525
-279
| -0.5% | -$22.5K | 0.03% | 602 |
|
|
2024
Q2 | $4.53M | Buy |
54,804
+2,155
| +4% | +$190K | 0.03% | 551 |
|
|
2024
Q1 | $4.49M | Sell |
52,649
-1,808
| -3% | -$142K | 0.03% | 550 |
|
|
2023
Q4 | $4.66M | Sell |
54,457
-433
| -0.8% | -$37.4K | 0.03% | 493 |
|
|
2023
Q3 | $4.92M | Sell |
54,890
-1,176
| -2% | -$105K | 0.04% | 410 |
|
|
2023
Q2 | $4.77M | Sell |
56,066
-389
| -0.7% | -$32.9K | 0.03% | 472 |
|
|
2023
Q1 | $4.67M | Sell |
56,455
-927
| -2% | -$75K | 0.03% | 488 |
|
|
2022
Q4 | $4.51M | Sell |
57,382
-920
| -2% | -$73.9K | 0.03% | 503 |
|
|
2022
Q3 | $4.32M | Sell |
58,302
-261
| -0.4% | -$18.7K | 0.04% | 484 |
|
|
2022
Q2 | $3.82M | Sell |
58,563
-1,521
| -3% | -$90K | 0.03% | 590 |
|
|
2022
Q1 | $3.8M | Buy |
60,084
+17,188
| +40% | +$935K | 0.02% | 696 |
|
|
2021
Q4 | $2.28M | Buy |
42,896
+283
| +0.7% | +$17.2K | 0.02% | 823 |
|
|
2021
Q3 | $3.01M | Sell |
42,613
-977
| -2% | -$61.7K | 0.03% | 635 |
|
|
2021
Q2 | $2.9M | Buy |
43,590
+17,338
| +66% | +$1.23M | 0.03% | 693 |
|
|
2021
Q1 | $2.91M | Sell |
26,252
-1,534
| -6% | -$190K | 0.03% | 690 |
|
|
2020
Q4 | $3.3M | Sell |
27,786
-1,241
| -4% | -$134K | 0.03% | 573 |
|
|
2020
Q3 | $2.53M | Sell |
29,027
-895
| -3% | -$78.2K | 0.03% | 620 |
|
|
2020
Q2 | $2.68M | Sell |
29,922
-20,473
| -41% | -$2.07M | 0.03% | 581 |
|
|
2020
Q1 | $5.02M | Sell |
50,395
-775
| -2% | -$84K | 0.07% | 253 |
|
|
2019
Q4 | $5.88M | Sell |
51,170
-436
| -0.8% | -$52.8K | 0.06% | 292 |
|
|
2019
Q3 | $6.51M | Sell |
51,606
-1,541
| -3% | -$196K | 0.07% | 252 |
|
|
2019
Q2 | $6.4M | Sell |
53,147
-108,349
| -67% | -$10.7M | 0.07% | 266 |
|
|
2019
Q1 | $14.1M | Buy |
161,496
+107,242
| +198% | +$9.75M | 0.04% | 354 |
|
|
2018
Q4 | $5.43M | Sell |
54,254
-132
| -0.2% | -$13.9K | 0.07% | 264 |
|
|
2018
Q3 | $6.23M | Sell |
54,386
-3,569
| -6% | -$369K | 0.06% | 278 |
|
|
2018
Q2 | $5.2M | Buy |
57,955
+34,009
| +142% | +$2.87M | 0.06% | 291 |
|
|
2018
Q1 | $1.75M | Hold |
23,946
| – | – | 0.02% | 818 |
|
|
2017
Q4 | $1.39M | Buy |
+23,946
| New | +$1.26M | 0.02% | 898 |
|
Other funds holding HAE
AI
MetLife Investment Management's HAE Position: Q2 2026 in Review
MetLife Investment Management increased its Haemonetics (HAE) stake by 2.2% in Q2 2026, buying an estimated $67.1K and bringing the position to 49,081 shares worth $3.68M. The position accounts for 0.02% of the portfolio, ranked #810.
MetLife Investment Management first reported a position in HAE in Q4 2017 and has held it in 35 quarters since. The position peaked at $24.7M in Q2 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- MetLife Investment Management held 49,081 shares of Haemonetics worth $3.68M as of Q2 2026.
- MetLife Investment Management bought 1,045 Haemonetics shares in Q2 2026, an estimated $67.1K.
- Haemonetics made up 0.02% of MetLife Investment Management's portfolio in Q2 2026, its #810 holding.
- MetLife Investment Management first reported a position in Haemonetics in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's Haemonetics position peaked at $24.7M in Q2 2025.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.